biostudies-literatureBawa ZThe Lambert Initiative for Cannabinoid Therapeuticse082927https://www.ebi.ac.uk/biostudies/studies/S-EPMC10966725biostudies-literatureUnknown14(3)<h4>Introduction</h4>The non-intoxicating plant-derived cannabinoid, cannabidiol (CBD), has demonstrated therapeutic potential in a number of clinical conditions. Most successful clinical trials have used relatively high (≥300 mg) oral doses of CBD. Relatively few studies have investigated the efficacy of lower (<300 mg) oral doses, typical of those available in over-the-counter CBD products.<h4>Methods</h4>We present a protocol for a randomised, double-blind, placebo-controlled, parallel-group clinical trial investigating the effects of a low oral dose (150 mg) of CBD on acute psychosocial stress, situational anxiety, motion sickness and cybersickness in healthy individuals. Participants (n=74) will receive 150 mg of CBD or a matched placebo 90 min before completing three virtual reality BMJ openEffects of cannabidiol on psychosocial stress, situational anxiety and nausea in a virtual reality environment: a protocol for a single-centre randomised clinical trial.PMC10966725This work was supported by The Lambert InitiativeMcCartney DBedoya-Perez MLau NSBawa ZMcGregor ISFox RMacDougall HfalseEffects of cannabidiol on psychosocial stress, situational anxiety and nausea in a virtual reality environment: a protocol for a single-centre randomised clinical trial.<h4>Introduction</h4>The non-intoxicating plant-derived cannabinoid, cannabidiol (CBD), has demonstrated therapeutic potential in a number of clinical conditions. Most successful clinical trials have used relatively high (≥300 mg) oral doses of CBD. Relatively few studies have investigated the efficacy of lower (<300 mg) oral doses, typical of those available in over-the-counter CBD products.<h4>Methods</h4>We present a protocol for a randomised, double-blind, placebo-controlled, parallel-group clinical trial investigating the effects of a low oral dose (150 mg) of CBD on acute psychosocial stress, situational anxiety, motion sickness and cybersickness in healthy individuals. Participants (n=74) will receive 150 mg of CBD or a matched placebo 90 min before completing three virtual reality 2024-01-01T00:00:00Z2024 Mar2026-07-15T15:29:11.003Z2024-12-03T23:55:46.933ZS-EPMC109667253853157210.1136/bmjopen-2023-082927